{"type":"trials","record":{"id":41426,"source_id":"clinicaltrials-gov","external_id":"NCT07317934","title":"Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)","brief_summary":"This is a Phase III, randomized, open-label, active-controlled study to evaluate the efficacy and safety of subretinal injection of LX102 in participants with neovascular age-related macular degeneration. The study will evaluate a single subretinal injection of LX102 compared to an active comparator. The primary endpoint of this study is the mean change from D0 in BCVA based on an average at weeks 48 and 56.","overall_status":"Recruiting","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Innostellar Biotherapeutics Co.,Ltd","enrollment":388,"countries":["China"],"start_date":"2026-01-14","completion_date":"2032-06-04","last_update_date":"2026-08-06","source_url":"https://clinicaltrials.gov/study/NCT07317934","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 80 Years","comparator":"Aflibercept","organization":"Innostellar Biotherapeutics Co.,Ltd","interventions":["LX102","Aflibercept"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean change from D0 in BCVA based on an average at weeks 48 and 56. — Week 56","Proportion of participants with improved BCVA — Week 56 and week 104","Proportion of participants with worsened BCVA — Week 56 and week 104","Mean change from D0 in CST based on an average at weeks 48 and 56 — Week 56","Proportion of participants without SRF/IRF on OCT at week 56 — Week 56","Proportion of participants who were supplemental anti-VEGF injection-free — Through 56 weeks","Proportion of participants who received 1 or 2 aflibercept injections — Through 56 weeks","Supplemental anti-VEGF injection annualized rate after LX102 administration through Week 56 — Through 56 weeks","Incidence of ocular and nonocular AEs and SAEs — 56 weeks","Immunogenicity characteristics of LX102 — 56 weeks"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular Age-Related Macular Degeneration (nAMD)","Wet AMD","LX102","Aflibercept"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct07317934","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2026-01-14 to 2032-06-04","comparator":"Aflibercept","confidence":"structured-source","population":"ALL · 50 Years to 80 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.810Z","intervention":["LX102","Aflibercept"],"participants":388,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean change from D0 in BCVA based on an average at weeks 48 and 56. — Week 56","Proportion of participants with improved BCVA — Week 56 and week 104","Proportion of participants with worsened BCVA — Week 56 and week 104","Mean change from D0 in CST based on an average at weeks 48 and 56 — Week 56","Proportion of participants without SRF/IRF on OCT at week 56 — Week 56","Proportion of participants who were supplemental anti-VEGF injection-free — Through 56 weeks","Proportion of participants who received 1 or 2 aflibercept injections — Through 56 weeks","Supplemental anti-VEGF injection annualized rate after LX102 administration through Week 56 — Through 56 weeks","Incidence of ocular and nonocular AEs and SAEs — 56 weeks","Immunogenicity characteristics of LX102 — 56 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41426","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}